全文获取类型
收费全文 | 9062篇 |
免费 | 643篇 |
国内免费 | 221篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 100篇 |
妇产科学 | 77篇 |
基础医学 | 735篇 |
口腔科学 | 95篇 |
临床医学 | 785篇 |
内科学 | 1324篇 |
皮肤病学 | 81篇 |
神经病学 | 1174篇 |
特种医学 | 200篇 |
外科学 | 253篇 |
综合类 | 779篇 |
一般理论 | 5篇 |
预防医学 | 763篇 |
眼科学 | 35篇 |
药学 | 2823篇 |
中国医学 | 619篇 |
肿瘤学 | 54篇 |
出版年
2024年 | 14篇 |
2023年 | 116篇 |
2022年 | 124篇 |
2021年 | 248篇 |
2020年 | 261篇 |
2019年 | 342篇 |
2018年 | 353篇 |
2017年 | 376篇 |
2016年 | 319篇 |
2015年 | 234篇 |
2014年 | 388篇 |
2013年 | 1551篇 |
2012年 | 377篇 |
2011年 | 416篇 |
2010年 | 364篇 |
2009年 | 317篇 |
2008年 | 347篇 |
2007年 | 359篇 |
2006年 | 351篇 |
2005年 | 270篇 |
2004年 | 248篇 |
2003年 | 249篇 |
2002年 | 222篇 |
2001年 | 172篇 |
2000年 | 146篇 |
1999年 | 139篇 |
1998年 | 130篇 |
1997年 | 127篇 |
1996年 | 115篇 |
1995年 | 85篇 |
1994年 | 129篇 |
1993年 | 71篇 |
1992年 | 73篇 |
1991年 | 83篇 |
1990年 | 66篇 |
1989年 | 78篇 |
1988年 | 48篇 |
1987年 | 50篇 |
1986年 | 74篇 |
1985年 | 106篇 |
1984年 | 118篇 |
1983年 | 67篇 |
1982年 | 67篇 |
1981年 | 43篇 |
1980年 | 35篇 |
1979年 | 11篇 |
1978年 | 15篇 |
1977年 | 11篇 |
1976年 | 8篇 |
1973年 | 4篇 |
排序方式: 共有9926条查询结果,搜索用时 234 毫秒
21.
小鼠吗啡依赖纳洛酮催促戒断跳跃反应模型的建立 总被引:1,自引:0,他引:1
目的建立稳定的小鼠吗啡依赖纳洛酮催促戒断跳跃反应模型。方法小鼠连续皮下注射吗啡,以纳洛酮催促戒断跳跃反应为指标,调整吗啡给予天数(5,6,7,10d)、吗啡累积剂量(360,560,640,945,1100,1105,1200mg/kg)、每日给予吗啡的频数[一天二次(bid),一天三次(tid)]、纳洛酮催促紧前给予吗啡与否、以及纳洛酮剂量(10,20mg/kg),建立四个造模方案包括八个子方案。结果方案A、B2、C2吗啡组小鼠跳跃反应率未达100%;方案B1、C1、D2、D3、D4吗啡组小鼠跳跃次数变异系数较大。方案D1采用小鼠连续皮下注射倍增剂量的吗啡,tid×6d,每日每次剂量分别为5,10,20,40,80,160mg/kg;第7天皮下注射吗啡160mg/kg,3h后腹腔注射纳洛酮10mg/kg,吗啡组小鼠可产生显著的跳跃反应,与对照组比较差异有显著性(P<0.01),且变异系数小(CV为0.22),该方案吗啡依赖小鼠跳跃反应次数适度,离散度小。结论选用方案D1可建立稳定的小鼠戒断跳跃反应模型。 相似文献
22.
23.
Xingguang Luo Henry R Kranzler Lingjun Zuo Shuang Wang Joel Gelernter 《Neuropsychopharmacology》2007,61(5):599-608
BACKGROUND: Personality traits are associated with substance dependence (SD); genetic factors may influence both. Strong associations between ADH4 variation and SD have been reported. We aimed to investigate the relationship between ADH4 variation and personality traits in the present study. METHODS: We assessed dimensions of the five-factor model of personality in 243 subjects with SD (175 European Americans [EAs] and 68 African Americans [AAs]) and 296 healthy control subjects (256 EAs and 40 AAs). We also genotyped 7 ADH4 markers (spanning the locus) and 38 unlinked ancestry-informative markers in these subjects. The relationships between the diplotypes, alleles, and genotypes at ADH4 and personality traits were examined using multivariate analysis of covariance (MANCOVA), controlling for potential confounders. RESULTS: Generally, SD patients, older individuals, and male subjects scored higher on neuroticism and lower on other personality factors. Personality factors were associated with the diplotypes. The allele A or genotype A/A of single nucleotide polymorphism (SNP)6 (rs1800759 at the gene promoter) was significantly associated with agreeableness scores. There were associations between extraversion and SNP1 (hcv2033010 at the 3' end) and SNP2 (rs1042364 in exon 9) in subjects with higher conscientiousness scores. CONCLUSIONS: The personality traits of agreeableness and extraversion are related to ADH4 polymorphism. Among the ADH4 markers that appear to predispose to certain personality traits, the functional variant rs1800759 (SNP6) in the promoter region is most important. We conclude that personality traits and SD have a partially overlapping genetic basis. 相似文献
24.
Ilana B. Crome 《Drugs (Abingdon, England)》2006,13(3):203-224
Over the last two decades there has been accumulating evidence that both psychosocial and pharmacological treatment interventions can effect change in substance-misusing adults. Thus, treatment interventions implemented for young people with substance problems largely draw on the adult addiction experience and that of child and adolescent psychiatry and psychology. As young people with problematic drug use have different treatment needs, and require different interventions and services to those of adults, results of adult studies cannot necessarily be directly extrapolated to young people.
Over the last five years evidence has been rapidly mounting that treatment may potentially work in young people, but as yet it is not as extensive as that for adults. The interventions that appear most fruitful are those based on learning theory, e.g. cognitive behavioural therapy and family therapy. Outcome studies in young people demonstrate substantial variability in substance use and misuse following treatment. From the UK perspective, the evidence is almost entirely USA based, and these evaluations of non-UK treatment programmes for young people cannot be simply transferred or transported to UK healthcare settings. This has significant implications for practice and policy.
At this stage, 'guidelines' or 'guidance' that is available is either not directed at young people and/or is largely gleaned from the USA literature. In addition, it does not adequately capture the complexity of cases at front-line specialist settings. The management of young substance misusers in the UK is, in the main, 'beyond guidelines and guidance'.
The restricted treatment service network for young people in the UK makes the potential for undertaking studies on treatment effectiveness extremely limited, but because there is evidence of a growing number of young people requiring treatment, such specialist drug services require evaluation. Serious consideration of the establishment and funding of evaluation of treatment interventions to be delivered to young substance misusers in the UK is urgently needed. 相似文献
Over the last five years evidence has been rapidly mounting that treatment may potentially work in young people, but as yet it is not as extensive as that for adults. The interventions that appear most fruitful are those based on learning theory, e.g. cognitive behavioural therapy and family therapy. Outcome studies in young people demonstrate substantial variability in substance use and misuse following treatment. From the UK perspective, the evidence is almost entirely USA based, and these evaluations of non-UK treatment programmes for young people cannot be simply transferred or transported to UK healthcare settings. This has significant implications for practice and policy.
At this stage, 'guidelines' or 'guidance' that is available is either not directed at young people and/or is largely gleaned from the USA literature. In addition, it does not adequately capture the complexity of cases at front-line specialist settings. The management of young substance misusers in the UK is, in the main, 'beyond guidelines and guidance'.
The restricted treatment service network for young people in the UK makes the potential for undertaking studies on treatment effectiveness extremely limited, but because there is evidence of a growing number of young people requiring treatment, such specialist drug services require evaluation. Serious consideration of the establishment and funding of evaluation of treatment interventions to be delivered to young substance misusers in the UK is urgently needed. 相似文献
25.
26.
Judith L. Marks PhD Elizabeth M. Hill PhD Cynthia S. Pomerleau PhD Sharon A. Mudd PhD Frederic C. Blow PhD 《Journal of substance abuse treatment》1997,14(6):337-527
We compared nicotine dependence and withdrawal in male alcoholic and control ever-smokers, controlling for relevant demographic and clinical variables. Alcoholics were more likely to meet criteria for moderate or severe nicotine dependence and endorse more nicotine dependence symptoms. Symptoms reported more frequently by alcoholics included: (a) using nicotine in larger amounts or over a longer time than intended; (b) continued use despite problems caused or exacerbated by nicotine; (c) marked tolerance; and (d) experiencing characteristic nicotine withdrawal symptoms. Alcoholics also smoked more heavily. Other than “headaches,” and “decreased heart rate,” alcoholics consistently endorsed nicotine withdrawal symptoms at a higher rate. After controlling for demographic and clinical variables and level of nicotine dependence, only “feel depressed” differed significantly between groups. Our research supports previous findings suggesting that nicotine dependence is more severe in those with a history of alcohol dependence. As a result, alcoholics may experience greater discomfort from nicotine withdrawal upon smoking cessation. 相似文献
27.
本实验研究血液与非血液灌流条件下缺血预处理(IP)对心肌的保护作用。应用离体大鼠Langendorf灌流模型,分血液灌流IP组、非血液(KrebsHenseleit液,KH液)灌流IP组及相应的对照组。测量心肌电生理特性等指标。结果与KH液灌流心脏相似,用血液灌流的大鼠心脏经IP后,在随后的停灌和复灌期间,心室颤动阈升高,心律失常发生率明显降低。实验结论为在用血液灌流离体大鼠心脏模型上,IP对心肌的保护作用与用生理溶液灌流的模型基本相同。 相似文献
28.
本文研究眼镜蛇入蛰前、蛰眠期及出蛰后血清 T_3,T_4和皮质醇水平与体内能量物质的含量变化关系,探讨其与蛰眠行为的关系。结果表明入蛰前眼镜蛇大量摄食储能过冬,由于血清激素水平降低,控制了体内组织器官的氧化代谢系统,使新陈代谢逐渐下降。蛰眠期血糖血脂明显下降,耗氧量显著减少,呈节能低代谢状态。此期血清激素水平已升高,但低温抑制了体内代谢。出蛰后血清激素水平明显升高且在春暖升温季节使眼镜蛇代谢率升高。 相似文献
29.
Bo-Lennart Johansson Ulla Berg Ulla Freyschuss Kerstin Hall Staffan Troell 《Pediatric nephrology (Berlin, Germany)》1990,4(6):589-592
The influence of metabolic control (HbA1c), noradrenaline (NA) and insulin-like growth factors (IGF-I and IGF-II) on renal function and size was investigated in 11 insulin-dependent diabetes mellitus patients aged 11–17 years. Renal function was evaluated in terms of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF). Renal size was determined as renal parenchymal volume (RPV) by ultrasonography. The patients' HbA1c values ranged from 8.2% to 12.9% (normal range 5.5–8.5%) and their GFR and ERPF were higher than normal. Their IGF-II values were higher, and NA and IGF-I levels were lower than those of healthy controls. Inverse correlations between NA and GFR (r=–0.66) and NA and ERPF (r=–0.63) were found. No correlation was found between serum IGF-I and renal functional parameters. The IGF-II values correlated with GFR and HbA1c (r=0.63,r=0.70 respectively). There were linear correlations between RPV and GFR, RPV and ERPF, HbA1c and GFR, and ERPF and RPV. Decreased NA concentrations and increased IGF-II values appear to be factors contributing to renal hyperfunction in these patients. 相似文献
30.
Mark Beuger md Anthony Tommasello ms Robert Schwartz md Mary Clinton pharmd 《Journal of substance abuse treatment》1998,15(6):15-593
Forty-eight consecutive applicants and 30 known clonidine-abusing methadone patients at three methadone treatment programs were surveyed regarding their use of clonidine. Two distinct patterns of clonidine use emerged. Of 22 applicants who took clonidine illicitly, 15 used it primarily to decrease opioid withdrawal, as well as for its sedating effect. Applicants mostly obtained it from physicians, used an average dose of 0.37 mg at a time, and about one third believed clonidine to be addictive. In contrast, clonidine-using patients took clonidine primarily for its psychoactive effects, including the interaction with methadone, in addition to decreasing opioid withdrawal. Patients obtained clonidine frequently on the street and from family or friends, but less from physicians. The average reported dose for patients was 0.6 mg. The vast majority of these patients felt clonidine was addictive. Our findings, when coupled with the risk inherent in clonidine overdose, suggest that further research into the identification and treatment of clonidine abuse among methadone patients is warranted. 相似文献